Health Care [ 9/12 ] | Biotechnology [ 42/73 ]
NASDAQ | Common Stock
Portage Biotech Inc., a clinical stage immune-oncology company, engages in the research and develops pharmaceutical and biotechnology products.
Its product pipeline comprises PORT-3, a polylactide-co-glycolide, which is in phase 1 to treat NY-ESO-1 positive tumors; PORT-6, a highly selective A2A receptor antagonist, which is in phase 1a for the treatment of solid tumors; PORT-8, a dual inhibitor of adenosine receptors 2A and 2B, which is in preclinical trial to treat solid tumors; PORT-9, an A2B antagonist, which is in pre-clinical stage program to treat colorectal and gastrointestinal cancers; PORT-4, a nanolipogel co-formulations to treat of solid tumors that is in preclinical trials; PORT-5, a VLP-STING to treat of solid tumors and is in preclinical trials; and PORT-7, a potent and selective antagonist of the adenosine A2B receptor.
Portage Biotech Inc. is based in Tortola, British Virgin Islands.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Sep 15, 25 | -2.88 Decreased by -28.90 K% | - |
| Nov 26, 24 | -1.26 Decreased by -335.83% | -0.28 Decreased by -351.39% |
| Aug 14, 24 | -1.26 Decreased by -281.21% | -0.24 Decreased by -424.17% |
| Jun 6, 24 | -24.20 Decreased by -351.49% | -0.22 Decreased by -10.90 K% |
| Feb 28, 24 | 0.01 Increased by +102.27% | -0.27 Increased by +103.70% |
| Nov 28, 23 | -0.29 Decreased by -383.33% | -0.28 Decreased by -3.57% |
| Aug 30, 23 | -0.33 Decreased by -153.85% | -0.24 Decreased by -37.50% |
| May 31, 23 | -5.36 Decreased by -857.14% | -5.36 |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 0.00 Decreased by N/A% | -1.36 M Increased by +73.63% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -1.66 M Increased by +72.02% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -24.89 M Increased by +73.65% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -39.37 M Decreased by -426.03% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -5.16 M Decreased by -443.52% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -5.92 M Decreased by -242.34% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -94.45 M Decreased by -965.64% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -7.49 M Decreased by -113.13% | Decreased by N/A% Decreased by N/A% |